Acute and 1-Year Hospitalization Costs for Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Results From the TRANSLATE-ACS Registry

Patricia A Cowper, J David Knight, Linda Davidson-Ray, Eric D Peterson, Tracy Y Wang, Daniel B Mark, TRANSLATE‐ACS Investigators, Patricia A Cowper, J David Knight, Linda Davidson-Ray, Eric D Peterson, Tracy Y Wang, Daniel B Mark, TRANSLATE‐ACS Investigators

Abstract

Background Hospitalization for acute myocardial infarction (MI) in the United States is both common and expensive, but those features alone provide little insight into cost-saving opportunities. Methods and Results To understand the cost drivers during hospitalization for acute MI and in the following year, we prospectively studied 11 969 patients with acute MI undergoing percutaneous coronary intervention at 233 US hospitals (2010-2013) from the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) registry. Baseline costs were collected in a random subset (n=4619 patients, 54% ST-segment-elevation MI [STEMI]), while follow-up costs out to 1 year were collected for all patients. The mean index length of stay was 3.1 days (for both STEMI and non-STEMI) and mean intensive care unit length of stay was 1.2 days (1.4 days for STEMI and 1.0 days for non-STEMI). Index hospital costs averaged $18 931 ($19 327 for STEMI, $18 465 for non-STEMI), with 45% catheterization laboratory-related and 20% attributable to postprocedure hospital stay. Patient factors, including severity of illness and extent of coronary disease, and hospital characteristics, including for profit status and geographic region, identified significant variations in cost. Intensive care was used for 53% of non-STEMI and increased costs by $3282. Postdischarge 1-year costs averaged $8037, and 48% of patients were rehospitalized (half within 2 months and 57% with a cardiovascular diagnosis). Conclusions While much of the cost of patients with acute MI treated with percutaneous coronary intervention is probably not modifiable by the care team, cost reductions are still possible through quality-preserving practice efficiencies, such as need-based use rather than routine use of intensive care unit for patients with stable non-STEMI. Clinical Trial Registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT00097591.

Keywords: acute myocardial infarction; cost; percutaneous coronary intervention.

Figures

Figure 1
Figure 1
Average marginal effects of baseline factors on index hospitalization cost. Estimated marginal effects, averaged over the sample, of baseline factors on cost of index hospitalization (point estimate with 95% CI). n=4611 (8 patients excluded because of missing independent variables). ACTION indicates Acute Coronary Treatment and Intervention Outcomes Network; CrCl, creatinine clearance; EF, ejection fraction; PHQ, Patient Health Questionnaire; STEMI, ST‐segment–elevation myocardial infarction; TIA, transient ischemic attack; VAS, visual analog scale.
Figure 2
Figure 2
Average marginal effects of procedures and complications on index hospitalization cost. Marginal effects, averaged over the sample, of procedures and complications on cost of index hospitalization (point estimate with 95% CI). Procedures and complications were added to the model with baseline factors (Figure 1). n=4611 (8 patients excluded because of missing independent variables). BMS indicates bare‐metal stent; CABG, coronary artery bypass grafting; DES, drug‐eluting stent; MI, myocardial infarction.
Figure 3
Figure 3
A, Cumulative incidence of hospitalizations during follow‐up. Cumulative incidence of first hospitalization (including emergency department encounters), accounting for the competing risk of death, over the 12‐month follow‐up period. B, Cumulative follow‐up costs, by clinical category. Cumulative mean costs at 1 month and at quarterly intervals over 1 year of follow‐up (total and stratified according to whether cardiovascular in nature). Vertical bars represent 95% CIs.
Figure 4
Figure 4
Average marginal effects of baseline and index factors on follow‐up cost. Estimated marginal effects, averaged over the sample, of baseline factors and events during index admission on cost of hospital care through 1 year (point estimate with 95% CI). n=10 328 (111 patients excluded due to missing independent variables). ADP indicates adenosine diphosphate; BMS, bare‐metal stent; bpm, beats per minute; CABG, coronary artery bypass grafting; CrCl, creatinine clearance; DES, drug‐eluting stent; EF, ejection fraction; GI/GU, gastrointestinal/genitourinary; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PHQ, Patient Health Questionnaire; STEMI, ST‐segment–elevation myocardial infarction; VAS, visual analog scale.
Figure 5
Figure 5
Estimated average marginal effects of baseline and index factors on probability of hospitalization. Estimated marginal effects, averaged over the sample, of baseline factors and events during index admission on probability of hospitalization through 1 year (point estimate with 95% CI). BMS indicates bare‐metal stent; CABG, coronary artery bypass grafting; CrCl, creatinine clearance; EF, ejection fraction; GI/GU, gastrointestinal/genitourinary; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; STEMI, ST‐segment–elevation myocardial infarction; VAS, visual analog scale.
Figure 6
Figure 6
Estimated average marginal effects of baseline and index factors on hospitalization costs for those hospitalized. Estimated marginal effects, averaged over the sample, of baseline factors and events during index admission on hospitalization costs (for those hospitalized) through 1 year (point estimate with 95% CI). ADP indicates adenosine diphosphate; BMS, bare‐metal stent; bpm, beats per minute; CABG, coronary artery bypass grafting; CrCl, creatinine clearance; EF, ejection fraction; GI/GU, gastrointestinal/genitourinary; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; STEMI, ST‐segment–elevation myocardial infarction; VAS, visual analog scale.

References

    1. Torio C, Moore B. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2013. HCUP Statistical Brief #204. May 2016. Rockville, MD: Agency for Healthcare Research and Quality; 2013. Available at: . Accessed January 29, 2019.
    1. Sugiyama T, Hasegawa K, Kobayashi Y, Takahashi O, Fukui T, Tsugawa Y. Differential time trends of outcomes and costs of care for acute myocardial infarction hospitalizations by ST elevation and type of intervention in the United States, 2001–2011. J Am Heart Assoc. 2015;4:e001445 DOI: 10.1161/JAHA.114.001445
    1. Kaplan RS, Haas DA. How not to cut health care costs. Harv Bus Rev. 2014;92:142.
    1. Dieleman JL, Squires E, Bui AL, Campbell M, Chapin A, Hamavid H, Horst C, Li Z, Matyasz T, Reynolds A, Sadat N, Schneider MT, Murray CJL. Factors associated with increases in US health care spending, 1996–2013. JAMA. 2017;318:1668–1678.
    1. Kaplan RS, Porter ME. How to solve the cost crisis in health care. Harv Bus Rev. 2011;89:46–52, 54, 56‐61 passim.
    1. Mark DB. Economics and cost effectiveness in cardiology In: Fuster V, Harrington RA, Narula J, Eapen ZJ, eds. Hurst's the Heart Manual of Cardiology. New York, NY: McGraw Hill; 2017.
    1. Tripathi A, Abbott JD, Fonarow GC, Khan AR, Barry NGt, Ikram S, Coram R, Mathew V, Kirtane AJ, Nallamothu BK, Hirsch GA, Bhatt DL. Thirty‐day readmission rate and costs after percutaneous coronary intervention in the United States: a National Readmission Database Analysis. Circ Cardiovasc Interv. 2017;10:e005925.
    1. Alyesh DM, Seth M, Miller DC, Dupree JM, Syrjamaki J, Sukul D, Dixon S, Kerr EA, Gurm HS, Nallamothu BK. Exploring the healthcare value of percutaneous coronary intervention: appropriateness, outcomes, and costs in Michigan hospitals. Circ Cardiovasc Qual Outcomes. 2018;11:e004328.
    1. van Diepen S, Tran DT, Ezekowitz JA, Zygun DA, Katz JN, Lopes RD, Newby LK, McAlister FA, Kaul P. The high cost of critical care unit over‐utilization for patients with NSTE ACS. Am Heart J. 2018;202:84–88.
    1. Janzon M, Henriksson M, Hasvold P, Hjelm H, Thuresson M, Jernberg T. Long‐term resource use patterns and healthcare costs after myocardial infarction in a clinical practice setting: results from a contemporary nationwide registry study. Eur Heart J Qual Care Clin Outcomes. 2016;2:291–298.
    1. Chin CT, Wang TY, Anstrom KJ, Zhu B, Maa JF, Messenger JC, Ryan KA, Davidson‐Ray L, Zettler M, Effron MB, Mark DB, Peterson ED. Treatment with adenosine diphosphate receptor inhibitors‐longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE‐ACS) study design: expanding the paradigm of longitudinal observational research. Am Heart J. 2011;162:844–851.
    1. Federspiel JJ, Anstrom KJ, Xian Y, McCoy LA, Effron MB, Faries DE, Zettler M, Mauri L, Yeh RW, Peterson ED, Wang TY; Treatment With Adenosine Diphosphate Receptor Inhibitors‐Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE‐ACS) Investigators. Comparing inverse probability of treatment weighting and instrumental variable methods for the evaluation of adenosine diphosphate receptor inhibitors after percutaneous coronary intervention. JAMA Cardiol. 2016;1:655–665.
    1. Centers for Medicare and Medicaid Services . Provider of Services Current Files. 2017. Available at: . Accessed October 17, 2017.
    1. Centers for Medicare and Medicaid Services . Cost Reports. 2017. Avaiable at: . Accessed October 17, 2017.
    1. Bureau of Labor Statistics . Databases, tables and calculators by subject. 2017. Accessed October 17, 2017.
    1. Centers for Medicare and Medicaid Services . Physician fee schedule look‐up tool. 2017. Available at: . Accessed October 17, 2017.
    1. Deb P, Norton EC, Manning WG. Health Econometrics Using Stata. College Station, TX: Stata Press; 2017.
    1. The University of Edinburgh . Grace ACS Risk Score. 2017. Available at: . Accessed October 17, 2017.
    1. Chin CT, Chen AY, Wang TY, Alexander KP, Mathews R, Rumsfeld JS, Cannon CP, Fonarow GC, Peterson ED, Roe MT. Risk adjustment for in‐hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry‐get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. Am Heart J. 2011;161:e2.
    1. Mathews R, Peterson ED, Chen AY, Wang TY, Chin CT, Fonarow GC, Cannon CP, Rumsfeld JS, Roe MT, Alexander KP. In‐hospital major bleeding during ST‐elevation and non‐ST‐elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry(R)‐GWTG. Am J Cardiol. 2011;107:1136–1143.
    1. Fanaroff AC, Chen AY, Thomas LE, Pieper KS, Garratt KN, Peterson ED, Newby LK, de Lemos JA, Kosiborod MN, Amsterdam EA, Wang TY. Risk score to predict need for intensive care in initially hemodynamically stable adults with non‐ST‐segment‐elevation myocardial infarction. J Am Heart Assoc. 2018;7:e008894 DOI: 10.1161/jaha.118.008894
    1. Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika. 2000;87:329–343.
    1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P. Heart disease and stroke statistics‐2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.
    1. Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, Barreto‐Filho JA, Kim N, Bernheim SM, Suter LG, Drye EE, Krumholz HM. Diagnoses and timing of 30‐day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309:355–363.
    1. Khot UN, Johnson MJ, Wiggins NB, Lowry AM, Rajeswaran J, Kapadia S, Menon V, Ellis SG, Goepfarth P, Blackstone EH. Long‐term time‐varying risk of readmission after acute myocardial infarction. J Am Heart Assoc. 2018;7:e009650 DOI: 10.1161/JAHA.118.009650
    1. Krumholz HM, Hsieh A, Dreyer RP, Welsh J, Desai NR, Dharmarajan K. Trajectories of risk for specific readmission diagnoses after hospitalization for heart failure, acute myocardial infarction, or pneumonia. PLoS One. 2016;11:e0160492.
    1. Hess CN, Shah BR, Peng SA, Thomas L, Roe MT, Peterson ED. Association of early physician follow‐up and 30‐day readmission after non‐ST‐segment‐elevation myocardial infarction among older patients. Circulation. 2013;128:1206–1213.
    1. Mathews R, Peterson ED, Honeycutt E, Chin CT, Effron MB, Zettler M, Fonarow GC, Henry TD, Wang TY. Early Medication nonadherence after acute myocardial infarction: insights into actionable opportunities from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment patterns and Events after Acute Coronary Syndrome (TRANSLATE‐ACS) study. Circ Cardiovasc Qual Outcomes. 2015;8:347–356.
    1. Lauzon C, Beck CA, Huynh T, Dion D, Racine N, Carignan S, Diodati JG, Charbonneau F, Dupuis R, Pilote L. Depression and prognosis following hospital admission because of acute myocardial infarction. CMAJ. 2003;168:547–552.
    1. van Galen LS, Cooksley T, Merten H, Brabrand M, Terwee CB, C HN, Subbe CP, Kidney R, Soong J, Vaughan L, Weichert I, Kramer MH, Nanayakkara PW. Physician consensus on preventability and predictability of readmissions based on standard case scenarios. Neth J Med. 2016;74:434–442.
    1. Wasfy JH, Strom JB, Waldo SW, O'Brien C, Wimmer NJ, Zai AH, Luttrell J, Spertus JA, Kennedy KF, Normand SL, Mauri L, Yeh RW. Clinical preventability of 30‐day readmission after percutaneous coronary intervention. J Am Heart Assoc. 2014;3:e001290 DOI: 10.1161/JAHA.114.001290
    1. Joynt Maddox KE, Orav EJ, Zheng J, Epstein AM. Evaluation of Medicare's bundled payments initiative for medical conditions. N Engl J Med. 2018;379:260–269.
    1. Guduguntla V, Syrjamaki JD, Ellimoottil C, Miller DC, Prager RL, Norton EC, Theurer P, Likosky DS, Dupree JM. Drivers of payment variation in 90‐day coronary artery bypass grafting episodes. JAMA Surg. 2018;153:14–19.
    1. Fanaroff AC, Peterson ED, Chen AY, Thomas L, Doll JA, Fordyce CB, Newby LK, Amsterdam EA, Kosiborod MN, de Lemos JA, Wang TY. Intensive care unit utilization and mortality among medicare patients hospitalized with non‐ST‐segment elevation myocardial infarction. JAMA Cardiol. 2017;2:36–44.
    1. Dayoub EJ, Nathan AS, Khatana SAM, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Groeneveld PW, Giri J. Use of prasugrel and ticagrelor in stable ischemic heart disease after percutaneous coronary intervention, 2009–2016. Circ Cardiovasc Interv. 2019;12:e007434.
    1. Afana M, Brinjikji W, Cloft H, Salka S. Hospitalization costs for acute myocardial infarction patients treated with percutaneous coronary intervention in the United States are substantially higher than Medicare payments. Clin Cardiol. 2015;38:13–19.
    1. Likosky DS, Van Parys J, Zhou W, Borden WB, Weinstein MC, Skinner JS. Association between Medicare expenditure growth and mortality rates in patients with acute myocardial infarction: a comparison from 1999 through 2014. JAMA Cardiol. 2018;3:114–122.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir